Monograph

J05AX07 - Enfuvirtide

Propably not porphyrinogenic

PNP

Side effects

Common side effects are decreased appetite and weight, anorexia, peripheral neuropathy and myalgia.

Rationale

Enfuvirtide is not an inhibitor of CYP3A4 or CYP1A2 in vivo.

Therapeutic characteristics

Enfuvirtide is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients.

Metabolism and pharmacokinetics

Enfuvirtide is a peptide and is expected to undergo catabolism to its constituent amino acids (SPC and Patel 2005). Elimination half-life is 3-4 hours. It is listed as a weak inhibitor of CYP3A4 (Isoherranen 2009), but in vivo studies has shown that enfuvirtide insignificantly inhibited CYP3A4 and that it has minimal inhibitory effect on CYP1A2. This indicates that it is has no or little influence on CYP3A4 and CYP1A2 (Patel 2005, SPC and Zhang 2004).

References

#	Citation details	PMID
*	Scientific articles
1.	Isoherranen, N., H. Hachad, et al. (2009). "Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database." Chem Res Toxicol 22(2): 294-298.
2.	Patel, I. H., X. Zhang, et al. (2005). "Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide." Clin Pharmacokinet 44(2): 175-186.
3.	Zhang, X., J. P. Lalezari, et al. (2004). "Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients." Clin Pharmacol Ther 75(6): 558-568.
*	Summary of Product Characteristics
4.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Enfuvirtide.

Citation details

PMID

Scientific articles

Isoherranen, N., H. Hachad, et al. (2009). "Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database." Chem Res Toxicol 22(2): 294-298.

Patel, I. H., X. Zhang, et al. (2005). "Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide." Clin Pharmacokinet 44(2): 175-186.

Zhang, X., J. P. Lalezari, et al. (2004). "Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients." Clin Pharmacol Ther 75(6): 558-568.

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Enfuvirtide.

Similar drugs

Explore alternative drugs in similar therapeutic classes J05A / J05AX or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands